Core Viewpoint - The stock of Clover Biopharmaceuticals-B (02197) has surged over 21%, reaching HKD 2.75 with a trading volume of HKD 42.22 million, following the announcement of the initiation of Phase I clinical trials for its respiratory combination vaccine candidates SCB-1022 and SCB-1033 [1] Group 1 - Clover Biopharmaceuticals has completed the enrollment of the first batch of trial participants for its RSV+hMPV vaccine candidate SCB-1022 and the RSV+hMPV+PIV3 candidate SCB-1033, marking the official start of Phase I clinical trials [1] - The CEO of Clover Biopharmaceuticals, Liang Guo, highlighted that while currently approved recombinant protein RSV vaccines are safe and effective, there remains a significant unmet clinical need globally [1] - The unmet clinical needs include the inability to prevent and alleviate respiratory diseases caused by human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3), which are structurally similar to RSV [1]
三叶草生物-B涨超21% 此前宣布启动呼吸道联合疫苗候选产品I期临床试验